Skip to content
Atlas Research Compounds

Bioregulatory peptides

Cortagen

A tetrapeptide investigated within short-peptide bioregulation research.

Evidence
Preclinical
Literature
Limited preclinical literature
Family
Short peptide bioregulator

Overview

Cortagen is discussed mainly in preclinical literature associated with tissue-specific peptide concepts. The catalog treats proposed mechanisms as hypotheses unless supported by independently reproduced molecular evidence.

Evidence maturity

Evidence score1/5

Preclinical foundation

The score summarizes evidence maturity, not safety, effectiveness, or suitability for any use.

Mechanism summary

Proposed as a tissue-associated short peptide bioregulator; target-level evidence remains limited.

Research category
Bioregulators
Editorial status
Published

Research timeline

Evidence stages describe maturity, not a chronological promise of development.

  1. Identity and target

    Documented

    The compound identity or proposed target is described in research literature.

  2. Preclinical research

    Emerging

    Preclinical support is limited, unclear, or not yet curated.

  3. Human research

    Not established

    A reliable human evidence base has not been established in this catalog.

  4. Independent synthesis

    Limited

    Independent replication and synthesis remain important evidence gaps.

Open research questions

  1. 01Are proposed tissue-specific effects independently reproducible?
  2. 02Which endpoints are mechanistic versus phenotypic?
  3. 03What analytical methods confirm peptide stability?

Literature starting points

These links support further review; inclusion is not an endorsement of every indexed conclusion.

  1. 01

    Short peptide bioregulator literature index

    PubMed, U.S. National Library of Medicine · Database

    Open source
  2. 02

    Atlas internal research database

    Internal Research Database · 2026 · Database

    Open source

Phase 2 study database

5 verified publications

Search all studies →
2011[Cortexin and cortagen as correcting agents in functional and metabolic disorders in the brain in chronic ischemia].Grade D2007Effects of bioactive tetrapeptides on free-radical processes.Grade D2004Elucidation of the effect of brain cortex tetrapeptide Cortagen on gene expression in mouse heart by microarray.Grade C2002The delayed effect of cortagen on the restoration of injured nerve function.Grade C2000Effect of tetrapeptide cortagen on regeneration of sciatic nerve.Grade C

Deep research cluster

Explore Cortagen by evidence question

MechanismMechanistic pathways reported in verified publications, separated from clinical inference.Human studiesVerified human publications, study designs, findings, and explicit limitations.Animal studiesPreclinical animal models and the boundaries on translating their results.Safety evidenceWhat the verified publication set can and cannot establish about safety.Research historyA publication timeline built only from verified study records.ComparisonsContextual links to related compounds and existing structured comparisons.

Related comparisons

Pinealon vs. CortagenSemax vs. CortagenCortagen vs. SemaxCortagen vs. SelankCortagen vs. ThymulinThymulin vs. Cortagen

Continue the research map

Related content

CompoundPinealonCompoundSemaxCompoundSelankVerified study[Cortexin and cortagen as correcting agents in functional and metabolic disorders in the brain in chronic ischemia].Verified studyEffects of bioactive tetrapeptides on free-radical processes.Verified studyElucidation of the effect of brain cortex tetrapeptide Cortagen on gene expression in mouse heart by microarray.ComparisonPinealon vs. CortagenComparisonSemax vs. CortagenComparisonCortagen vs. SemaxComparisonCortagen vs. SelankComparisonCortagen vs. ThymulinComparisonThymulin vs. CortagenTopic hubNeuroprotectionTopic hubPeptide Research